Crinetics Pharmaceuticals, Inc. Debt Securities, Available-for-sale
Crinetics Pharmaceuticals, Inc. (CRNX) had Debt Securities, Available-for-sale of $1.14 billion as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2025-08-07
- 2025-06-30: Debt Securities, Available-for-sale $1.14B.
- 2025-03-31: Debt Securities, Available-for-sale $1.18B.
- 2024-12-31: Debt Securities, Available-for-sale $1.09B.
- 2024-09-30: Debt Securities, Available-for-sale $545.40M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2025-06-30 | $1.14B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.18B 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.09B 10-Q · filed 2025-08-07 | |
| 2024-09-30 | $545.40M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $560.79M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $505.04M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $503.66M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $411.86M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $224.98M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $254.93M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $301.75M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $337.45M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $346.21M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $174.18M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $133.01M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $31.79M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $24.99M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $133.01M 10-Q · filed 2022-08-12 | $45.09M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $77.79M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $69.00M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $44.35M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $61.88M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $78.07M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $65.09M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $85.26M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $94.38M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $118.90M 10-K · filed 2020-03-09 |